MedTrace Logo

Population Pharmacokinetics of Imatinib in CML Patients in Iran

NCT02146846 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2016-09-07

No results posted yet for this study

Summary

The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.

Conditions

  • Chronic Myelogenous Leukemia

Interventions

DRUG

Imatinib

Patients with chronic myeloid leukemia who receive Imatinib as treatment

Sponsors & Collaborators

  • Kerman University of Medical Sciences

    lead OTHER

Principal Investigators

  • ehsan mohajeri, Ph.D. · Department of pharmaceutics, Faculty of pharmacy, Kerman University of medical sciences

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-04-30
Completion
2017-07-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146846 on ClinicalTrials.gov